ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1548

Diagnosis Pathways in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

Paul Dolin1, Danuta Kielar1, Anat Shavit1, Karina Keogh2, Jennifer Rowell1, Chris Edmonds3, Juliana Meyers4, Elizabeth Esterberg4, Tram Nham4 and Stephanie Chen5, 1AstraZeneca, Cambridge, United Kingdom, 2Mayo Clinic, Rochester, MN, 3AstraZeneca, Gaithersburg, MD, 4RTI Health Solutions, Research Triangle Park, NC, 5BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

Meeting: ACR Convergence 2023

Keywords: Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Raising awareness of eosinophilic granulomatosis with polyangiitis (EGPA), a rare necrotizing small-to-medium vessel vasculitis, amongst clinicians is important to ensure timely diagnosis and treatment. EGPA is associated with substantial disease burden and impact on health-related quality of life, with patients often facing a long and complex pathway from symptom onset to diagnosis. We aimed to characterize the diagnostic journey of patients with EGPA using a retrospective analysis of US administrative health insurance claims (Merative™ MarketScan® databases).

Methods: Patients with newly diagnosed EGPA from 2017 to 2021 with ≥12 months of continuous pre-diagnosis health plan enrollment and ≥1 inpatient or ≥2 outpatient EGPA-related diagnoses (≥90 days apart, ICD-10-CM code M30.1) were included. Follow-up was from date of first observed EGPA diagnosis (index date; ID) until health plan disenrollment or database end. Drug therapies and outpatient visits prior to ID, specialties making incident EGPA diagnosis, time from first observed symptom to ID, and persistent vasculitic damage were analyzed.

Results: In total, 236 patients with incident EGPA were identified; 88% had commercial insurance. At ID, mean (standard deviation [SD]) age was 50.4 (14.5) years, 88% were < 65 years, and 58% were female. In the year before ID, 80% of patients were receiving systemic glucocorticoids, most commonly oral glucocorticoids (OGCs; 77%), 13.6% were receiving immunosuppressants, and 12.7% biologics. Among the 164 patients receiving prednisone, the mean (SD) daily dose was 28 (17) mg, for a mean (SD) of 3.2 (3.5) months. In the year before ID, 96% of patients had at least one outpatient visit; most frequently family practice (50%) and internal medicine (45%). The most frequent (mean [SD]) outpatient visits were to allergy and immunology (6.2 [8.0]), family practice (4.7 [4.2]), internal medicine (4.3 [3.6]), otolaryngology (3.7 [3.0]), and pulmonary disease (3.3 [4.4]). Overall, 31% and 70% of patients had their first observed EGPA diagnosis in an inpatient and/or outpatient setting, respectively, which were most commonly made by acute care hospital specialists, followed by internal medicine, and pulmonary disease specialists (Figure 1). The mean (SD) time from first observed EGPA symptom or organ damage in the claims record to first observed EGPA diagnosis was 25.0 (15.0) months, with >99% of patients experiencing symptoms or organ damage prior to their first observed diagnosis. At ID, 95% of patients had persistent damage to at least one organ. Most patients had pulmonary damage, followed by ear, nose, and throat, and cardiovascular damage (Table 1).

Conclusion: Prior to their first observed diagnosis, most patients with EGPA were prescribed OGCs and made frequent health care provider (HCP) visits. At the time of their first observed diagnosis, the vast majority of patients had already experienced an EGPA event/organ damage for >2 years.These data highlight that greater awareness of EGPA is needed amongst HCPs to facilitate more rapid diagnosis, minimize organ damage, reduce exposure to therapies with harmful side effects, and better enable a multidisciplinary approach.

Supporting image 1

Supporting image 2


Disclosures: P. Dolin: AstraZeneca, 3, 11; D. Kielar: AstraZeneca, 3, 11; A. Shavit: AstraZeneca, 3, 11; K. Keogh: AstraZeneca, 12, site PI for an AstraZeneca pharmaceutical trial in asthma; J. Rowell: AstraZeneca, 3, 11; C. Edmonds: AstraZeneca, 3, 11; J. Meyers: AstraZeneca, 12, Employee of RTI Health Solutions, which received funding from AstraZeneca to conduct the study; E. Esterberg: AstraZeneca, 12, Employee of RTI Health Solutions, which received funding from AstraZeneca to conduct the study; T. Nham: AstraZeneca, 12, Employee of RTI Health Solutions, which received funding from AstraZeneca to conduct the study; S. Chen: AstraZeneca, 3, 11.

To cite this abstract in AMA style:

Dolin P, Kielar D, Shavit A, Keogh K, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen S. Diagnosis Pathways in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/diagnosis-pathways-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis-egpa-a-retrospective-analysis-of-us-health-insurance-claims-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnosis-pathways-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis-egpa-a-retrospective-analysis-of-us-health-insurance-claims-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology